Enhanced platelet activation following coronary stent implantation in patients on hemodialysis

Cardiovascular Intervention and Therapeutics

Volumn 25, Issue 2, 2010, Pages 72-77

  Fu, Qiang ^a   Ishikawa, Shuichi ^a   Yokoyama, Naoyuki ^a   Kozuma, Ken ^a   Takada, Kaoru ^a   Muraki, Aki ^a   Isshiki, Takaaki ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Hemodialysis; Percutaneous coronary intervention ("PCI"); Platelet activation; Platelet aggregation

Indexed keywords

EID: 84873641366     PISSN: 18684300     EISSN: 18684297     Source Type: Journal    
DOI: 10.1007/s12928-010-0013-4     Document Type: Article

References (28)

1. Gruberg L, Mintz GS, Mehran R, Gangas G, Lansky AJ, Kent KM, et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol. 2000;36:1542-8.
2. Rubenstein MH, Harrell LC, Sheynberg BV, Schunkert H, Bazari H, Palacios IF. Are patients with renal failure good candidates for percutaneous coronary revascularization in the new device era? Circulation. 2000;102:2966-72.
3. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med. 1998;339:799-805.
4. Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol. 1999; 10:1606-15.
5. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126-30.
6. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49:1505-16.
7. Cuisset T, Frere C, Quilici J, Barbou F, Morange PE, Hovasse T, et al. High post-treatment platelet reactivity identified lowresponders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost. 2006;4:542-9.
8. Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, et al. Platelet reactivity in patients and recurrent events poststenting: results of the prepare post-stenting study. J Am Coll Cardiol. 2005;46:1820-6.
9. Ozeki Y, Sudo T, Toga K, Nagamura Y, Ito H, Ogawa T, et al. Characterization of whole blood aggregation with a new type of aggregometer by a screen filtration pressure method. Thromb Res. 2001;101:65-72.
10. Casserly LF, Dember LM. Thrombosis in end-stage renal disease. Semin Dial. 2003;16:245-56.
11. Di Minno G, Martinez J, McKean ML, De La Rosa J, Burke JF, Murphy S. Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis. Am J Med. 1985;79:552-9.
12. Di Minno G, Cerbone A, Usberti M, Cianciaruso B, Cortese A, Farace MJ, et al. Platelet dysfunction in uremia. II. Correction by arachidonic acid of the impaired exposure of fibrinogen receptors by adenosine diphosphate or collagen. J Lab Clin Med. 1986;108:246-52.
13. Mezzano D, Tagle R, Panes O, Perez M, Downey P, Munoz B, et al. Hemostatic disorder of uremia: the platelet defect, main determinant of the prolonged bleeding time, is correlated with indices of activation of coagulation and fibrinolysis. Thromb Haemost. 1996;76:312-21.
14. Burgstahler C, Geisler T, Lindemann S, Brodoefel H, Reimann A, Heuschmid M, et al. Elevated coronary calcium scores are associated with higher residual platelet aggregation after clopidogrel treatment in patients with stable angina pectoris. Int J Cardiol. 2009;135:132-5.
15. Cases A, Reverter JC, Escolar G, Sanz C, Lopez-Pedret J, Revert L, et al. Platelet activation on hemodialysis: influence of dialysis membranes. Kidney Int Suppl. 1993;41:S217-20.
16. Deguchi N, Ohigashi T, Tazaki H, Handa M, Ikeda Y. Haemodialysis and platelet activation. Nephrol Dial Transplant. 1991;6(Suppl 2):40-2.
17. Reverter JC, Escolar G, Sanz C, Cases A, Villamor N, Nieuwenhuis HK, et al. Platelet activation during hemodialysis measured through exposure of p-selectin: analysis by flow cytometric and ultrastructural techniques. J Lab Clin Med. 1994;124:79-85.
18. Kawabata K, Nagake Y, Shikata K, Fukuda S, Nakazono H, Takahashi M, et al. Soluble p-selectin is released from activated platelets in vivo during hemodialysis. Nephron. 1998;78:148-55.
19. Sirolli V, Strizzi L, Di Stante S, Robuffo I, Procopio A, Bonomini M. Platelet activation and platelet-erythrocyte aggregates in endstage renal disease patients on hemodialysis. Thromb Haemost. 2001;86:834-9.
20. Bonomini M, Sirolli V, Settefrati N, Stuard S, Tropea F, Di Liberato L, et al. Surface antigen expression and platelet neutrophil interactions in haemodialysis. Blood Purif. 1999;17:107-17.
21. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357:2482-94.
22. Moshfegh K, Redondo M, Julmy F, Wuillemin WA, Gebauer MU, Haeberli A, et al. Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy. J Am Coll Cardiol. 2000;36:699-705.
23. Jin RC, Voetsch B, Loscalzo J. Endogenous mechanisms of inhibition of platelet function. Microcirculation. 2005;12:247-58.
24. Catella-Lawson F, McAdam B, Morrison BW, Kapoor S, Kujubu D, Antes L, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther. 1999;289:735-41.
25. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (cox)-2: the human pharmacology of a selective inhibitor of cox-2. Proc Natl Acad Sci USA. 1999;96:272-7.
26. Moncada S. Adventures in vascular biology: a tale of two mediators. Philos Trans R Soc Lond B Biol Sci. 2006;361:735-59.
27. Annuk M, Lind L, Linde T, Fellstrom B. Impaired endotheliumdependent vasodilatation in renal failure in humans. Nephrol Dial Transplant. 2001;16:302-6.
28. Gurbel PA, Bliden KP, Hiatt BL, O' Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107: 2908-13.